Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 19.63M | 14.92M | 9.83M | 26.54M | 11.24M |
Gross Profit | 16.28M | -59.21M | 3.74M | 26.46M | 11.24M |
EBITDA | -58.83M | -85.89M | -51.99M | -40.11M | -27.93M |
Net Income | -60.48M | -86.88M | -61.23M | -40.78M | -28.35M |
Balance Sheet | |||||
Total Assets | 30.46M | 89.55M | 72.15M | 35.45M | 58.46M |
Cash, Cash Equivalents and Short-Term Investments | 17.91M | 77.61M | 52.00M | 28.55M | 51.79M |
Total Debt | 2.48M | 3.12M | 40.16M | 2.63M | 3.44M |
Total Liabilities | 58.37M | 63.02M | 101.28M | 9.43M | 8.31M |
Stockholders Equity | -27.91M | 26.53M | -49.26M | 11.63M | 35.76M |
Cash Flow | |||||
Free Cash Flow | -60.04M | -82.31M | -12.23M | -39.20M | -27.45M |
Operating Cash Flow | -59.92M | -81.18M | -7.57M | -37.33M | -27.01M |
Investing Cash Flow | -123.00K | 72.41M | -32.56M | -1.87M | -440.00K |
Financing Cash Flow | 344.00K | 62.18M | 35.77M | 15.96M | 72.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $8.92M | 4.67 | -41.13% | ― | ― | ― | |
52 Neutral | kr5.61B | 10.15 | -63.86% | 2.10% | 27.11% | 26.73% | |
49 Neutral | $9.21M | ― | -451.34% | ― | ― | -57.84% | |
42 Neutral | $15.27M | ― | -362.79% | ― | 32.45% | 39.31% | |
39 Underperform | $12.55M | ― | -285.79% | ― | ― | 23.65% | |
34 Underperform | $8.16M | ― | -126.03% | ― | -100.00% | -27.44% |
On January 6, 2025, Carisma Therapeutics was notified by Nasdaq that it failed to meet the minimum bid price requirement for continued listing on the Nasdaq Global Market. Despite being given a grace period until July 7, 2025, the company did not regain compliance, leading to a potential delisting threat. Following a hearing, Nasdaq allowed Carisma to transfer its listing to the Nasdaq Capital Market effective June 12, 2025, with a deadline to meet all listing criteria by October 7, 2025. To address this, Carisma scheduled a special stockholders’ meeting for August 5, 2025, to approve a reverse stock split aimed at increasing its share price and maintaining its listing status.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
On June 22, 2025, Carisma Therapeutics announced a merger agreement with OrthoCellix, a subsidiary of Ocugen, to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The merger will result in OrthoCellix owning approximately 90% of the combined entity, with plans to initiate a Phase 3 clinical trial for its NeoCart® technology by the end of 2025, potentially impacting the market for cartilage repair solutions.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.